Normally, the response rate in patients with other solid tumors when receiving anti-PD-1/PD-L1 antibodies hangs on multifactorial parameters, including PD-L1 expression, tumor mutational load/microsatellites status, and intensity of intratumoural CD8+ cytotoxic T cells (11–13). Here, CD274 is linked to neoplasm.